214 related articles for article (PubMed ID: 37936712)
1. Current knowledge of TNF-α monoclonal antibody infliximab in treating Kawasaki disease: a comprehensive review.
Chen J; Liao J; Xiang L; Zhang S; Yan Y
Front Immunol; 2023; 14():1237670. PubMed ID: 37936712
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of infliximab in the treatment of Kawasaki disease: A systematic review and meta-analysis.
Wang L; He M; Wang W; Li S; Zhao G
Eur J Pediatr; 2024 Apr; 183(4):1765-1776. PubMed ID: 38240765
[TBL] [Abstract][Full Text] [Related]
3. TNF-α blockers for the treatment of Kawasaki disease in children.
Yamaji N; da Silva Lopes K; Shoda T; Ishitsuka K; Kobayashi T; Ota E; Mori R
Cochrane Database Syst Rev; 2019 Aug; 8(8):CD012448. PubMed ID: 31425625
[TBL] [Abstract][Full Text] [Related]
4. Intravenous immunoglobulin for the treatment of Kawasaki disease.
Broderick C; Kobayashi S; Suto M; Ito S; Kobayashi T
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD014884. PubMed ID: 36695415
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.
Mori M; Imagawa T; Hara R; Kikuchi M; Hara T; Nozawa T; Miyamae T; Yokota S
J Rheumatol; 2012 Apr; 39(4):864-7. PubMed ID: 22337241
[TBL] [Abstract][Full Text] [Related]
6. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.
Han CL; Zhao SL
Med Sci Monit; 2018 Oct; 24():7264-7270. PubMed ID: 30307902
[TBL] [Abstract][Full Text] [Related]
7. [Retrospective analysis of infliximab in the treatment of Kawasaki disease].
Xie LP; Zhao L; Chu C; He L; Liang XC; Sun SN; Zhao QM; Wang F; Cao YY; Lin YX; Zeng ZQ; Wu L; Huang GY; Liu F
Zhonghua Er Ke Za Zhi; 2022 Jan; 60(1):14-19. PubMed ID: 34986617
[No Abstract] [Full Text] [Related]
8. Plasma exchange and infliximab as a third-line therapy for refractory infantile Kawasaki disease.
Ansai H; Masuda H; Nakao H; Nishimura N; Kubota M
Pediatr Int; 2022 Jan; 64(1):e15226. PubMed ID: 35831245
[TBL] [Abstract][Full Text] [Related]
9. Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin.
Burns JC; Song Y; Bujold M; Shimizu C; Kanegaye JT; Tremoulet AH; Franco A
Clin Exp Immunol; 2013 Dec; 174(3):337-44. PubMed ID: 23901839
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional regulation by infliximab therapy in Kawasaki disease patients with immunoglobulin resistance.
Ogihara Y; Ogata S; Nomoto K; Ebato T; Sato K; Kokubo K; Kobayashi H; Ishii M
Pediatr Res; 2014 Sep; 76(3):287-93. PubMed ID: 24964229
[TBL] [Abstract][Full Text] [Related]
11. Infliximab is the new kid on the block in Kawasaki disease: a single-centre study over 8 years from North India.
Singh S; Sharma D; Suri D; Gupta A; Rawat A; Rohit MK
Clin Exp Rheumatol; 2016; 34(3 Suppl 97):S134-8. PubMed ID: 27086575
[TBL] [Abstract][Full Text] [Related]
12. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.
Burns JC; Best BM; Mejias A; Mahony L; Fixler DE; Jafri HS; Melish ME; Jackson MA; Asmar BI; Lang DJ; Connor JD; Capparelli EV; Keen ML; Mamun K; Keenan GF; Ramilo O
J Pediatr; 2008 Dec; 153(6):833-8. PubMed ID: 18672254
[TBL] [Abstract][Full Text] [Related]
13. Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis.
Li X; Tang Y; Ding Y; Chen Y; Hou M; Sun L; Qian G; Qin L; Lv H
Eur J Pharmacol; 2021 May; 899():173985. PubMed ID: 33652059
[TBL] [Abstract][Full Text] [Related]
14. Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review.
Crayne CB; Mitchell C; Beukelman T
Pediatr Rheumatol Online J; 2019 Nov; 17(1):77. PubMed ID: 31775898
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of infliximab for the treatment of Kawasaki disease refractory to the initial treatment: A retrospective cohort study.
Takura T; Horiuchi S
J Cardiol; 2022 Aug; 80(2):172-178. PubMed ID: 35341683
[TBL] [Abstract][Full Text] [Related]
16. Analysis of biomarker serum levels in IVIG and infliximab refractory Kawasaki disease patients.
Hachiya A; Kobayashi N; Matsuzaki S; Takeuchi Y; Akazawa Y; Shigemura T; Motoki N; Masumoto J; Agematsu K
Clin Rheumatol; 2018 Jul; 37(7):1937-1943. PubMed ID: 29302828
[TBL] [Abstract][Full Text] [Related]
17. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
[TBL] [Abstract][Full Text] [Related]
18. Infliximab plus plasma exchange rescue therapy in Kawasaki disease.
Sonoda K; Mori M; Hokosaki T; Yokota S
J Pediatr; 2014 May; 164(5):1128-1132.e1. PubMed ID: 24560183
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.
Lei WT; Chang LS; Zeng BY; Tu YK; Uehara R; Matsuoka YJ; Su KP; Lee PC; Cavalcante JL; Stubbs B; Lin PY; Wu YC; Hsu CW; Chen TY; Chen YW; Yeh PY; Sun CK; Tseng PT; Kao YH
EBioMedicine; 2022 Apr; 78():103946. PubMed ID: 35306339
[TBL] [Abstract][Full Text] [Related]
20. [Kawasaki disease: what you need to know].
Bajolle F; Laux D
Arch Pediatr; 2012 Nov; 19(11):1264-8. PubMed ID: 22921712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
